Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment

Limited information is available in relation to surveillance, genotyping, genome sequences, and treatment outcomes for rare hepatitis C virus variants. Here, we have characterized a novel subtype of major hepatitis C virus genotype 1, which was deep sequenced before and after treatment failure with 4 weeks of glecaprevir and pibrentasvir.

Download Full-text

Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o

Virology Journal ◽

10.1186/s12985-019-1135-7 ◽

2019 ◽

Vol 16 (1) ◽

Cited By ~ 2

Author(s):

Bo Wang ◽

Luise Krüger ◽

Patrycja Machnowska ◽

Amare Eshetu ◽

Barbara Gunsenheimer-Bartmeyer ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Hiv 1

Download Full-text

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure

Hepatology ◽

10.1002/hep.29671 ◽

2018 ◽

Vol 67 (4) ◽

pp. 1253-1260 ◽

Cited By ~ 80

Author(s):

Fred Poordad ◽

Stanislas Pol ◽

Armen Asatryan ◽

Maria Buti ◽

David Shaw ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Treatment Failure ◽

Antiviral Treatment ◽

Genotype 1 ◽

Virus Genotype ◽

Direct Acting Antiviral ◽

Direct Acting

Download Full-text

Erratum for Mokhtari et al., Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV Genotype II Assay Using the New Abbott HCV GenotypePlusRUO Test

Journal of Clinical Microbiology ◽

10.1128/jcm.01356-16 ◽

2016 ◽

Vol 54 (9) ◽

pp. 2402-2402

Author(s):

Camelia Mokhtari ◽

Anne Ebel ◽

Birgit Reinhardt ◽

Sandra Merlin ◽

Stéphanie Proust ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Hcv Genotype ◽

Genotype Ii

Download Full-text

The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy

Journal of Viral Hepatitis ◽

10.1111/jvh.12132 ◽

2013 ◽

Vol 21 (3) ◽

pp. 208-215 ◽

Cited By ~ 25

Author(s):

M. Backx ◽

A. Lewszuk ◽

J. R. White ◽

J. Cole ◽

A. Sreedharan ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Treatment Failure ◽

Resource Use ◽

Virological Response ◽

Response To Therapy ◽

Genotype 1 ◽

Virus Genotype ◽

Cost Of Treatment ◽

The Cost

Download Full-text

Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV Genotype II Assay Using the New Abbott HCV GenotypePlusRUO Test

Journal of Clinical Microbiology ◽

10.1128/jcm.02264-15 ◽

2015 ◽

Vol 54 (2) ◽

pp. 296-299 ◽

Cited By ~ 11

Author(s):

Camelia Mokhtari ◽

Anne Ebel ◽

Birgit Reinhardt ◽

Sandra Merlin ◽

Stéphanie Proust ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Core Region ◽

Genotype 1 ◽

Virus Genotype ◽

Hcv Genotype ◽

The Core ◽

Hcv Genotyping ◽

Genotype Ii

Hepatitis C virus (HCV) genotyping continues to be relevant for therapeutic strategies. Some samples are reported as genotype 1 (gt 1) without subtype by the Abbott RealTime HCV Genotype II (GT II) test. To characterize such samples further, the Abbott HCV GenotypePlusRUO (Plus) assay, which targets the core region for gt 1a, gt 1b, and gt 6 detection, was evaluated as a reflex test in reference to NS5B or 5′-untranslated region (UTR)/core region sequencing. Of 3,626 routine samples, results of gt 1 without subtype were received for 171 samples (4.7%), accounting for 11.5% of gt 1 specimens. The Plus assay and sequencing were applied to 98 of those samples. NS5B or 5′-UTR/core region sequencing was successful for 91/98 specimens (92.9%). Plus assay and sequencing results were concordant for 87.9% of specimens (80/91 samples). Sequencing confirmed Plus assay results for 82.6%, 85.7%, 100%, and 89.3% of gt 1a, gt 1b, gt 6, and non-gt 1a/1b/6 results, respectively. Notably, 12 gt 6 samples that had been identified previously as gt 1 without subtype were assigned correctly here; for 25/28 samples reported as “not detected” by the Plus assay, sequencing identified the samples as gt 1 with subtypes other than 1a/1b. The genetic variability of HCV continues to present challenges for the current genotyping platforms regardless of the applied methodology. Samples identified by the GT II assay as gt 1 without subtype can be further resolved and reliably characterized by the new Plus assay.

Download Full-text